α-Amyrin attenuates high fructose diet-induced metabolic syndrome in rats

Appl Physiol Nutr Metab. 2017 Jan;42(1):23-32. doi: 10.1139/apnm-2016-0088. Epub 2016 Sep 2.

Abstract

This study investigated the effect of α-amyrin (a pentacyclic triterpene) on high-fructose diet (HFD)-induced metabolic syndrome in rats. Male Wistar rats were randomly distributed into different groups. The control group was fed normal rat chow diet. The HFD group was fed HFD (60%; w/w) for 42 days. Pioglitazone (10 mg/kg, orally, once daily) was used as a standard drug. α-Amyrin was administered in 3 doses (50, 100, and 200 mg/kg, orally, once daily along with HFD). Plasma glucose, total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C) were estimated. Changes in blood pressure, oral glucose tolerance, and insulin tolerance were measured. Hepatic oxidative stress as well as messenger RNA (mRNA) and protein levels of peroxisome proliferator-activated receptor alpha (PPAR-α) were analyzed. A significant increase in systolic blood pressure, plasma glucose, total cholesterol, and plasma triglycerides and a significant decrease in HDL-C were observed in HFD rats as compared with control rats. Glucose tolerance and insulin tolerance were also significantly impaired with HFD. α-Amyrin prevented these changes in a dose-dependent manner. Hepatic oxidative stress as well as micro- and macrovesicular fatty changes in hepatocytes caused by HFD were also attenuated by α-amyrin. α-Amyrin preserved the hepatic mRNA and protein levels of PPAR-α, which was reduced in HFD group. This study thus demonstrates that α-amyrin attenuates HFD-induced metabolic syndrome in rats.

Keywords: PPAR-α; high-fructose diet; metabolic syndrome; oxidative stress; régime riche en fructose; stress oxydatif; syndrome métabolique; α-amyrin; α-amyrine.

MeSH terms

  • Administration, Oral
  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use
  • Antioxidants / administration & dosage
  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • Diet, Carbohydrate Loading / adverse effects*
  • Dose-Response Relationship, Drug
  • Fructose / adverse effects*
  • Gene Expression Regulation / drug effects
  • Hyperglycemia / etiology
  • Hyperglycemia / prevention & control
  • Hyperlipidemias / etiology
  • Hyperlipidemias / prevention & control
  • Hypertension / etiology
  • Hypertension / prevention & control
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use
  • Insulin Resistance
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / metabolism
  • Metabolic Syndrome / pathology
  • Metabolic Syndrome / prevention & control*
  • Oleanolic Acid / administration & dosage
  • Oleanolic Acid / adverse effects
  • Oleanolic Acid / analogs & derivatives*
  • Oleanolic Acid / therapeutic use
  • Oxidative Stress / drug effects*
  • PPAR alpha / agonists
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • Random Allocation
  • Rats, Wistar

Substances

  • Antihypertensive Agents
  • Antioxidants
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • PPAR alpha
  • Fructose
  • Oleanolic Acid
  • beta-amyrin